200 related articles for article (PubMed ID: 9053847)
1. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells.
Ogretmen B; Safa AR
Oncogene; 1997 Jan; 14(4):499-506. PubMed ID: 9053847
[TBL] [Abstract][Full Text] [Related]
2. p53 mutational status and survival of human breast cancer MCF-7 cell variants after exposure to X rays or fission neutrons.
Balcer-Kubiczek EK; Yin J; Lin K; Harrison GH; Abraham JM; Meltzer SJ
Radiat Res; 1995 Jun; 142(3):256-62. PubMed ID: 7761574
[TBL] [Abstract][Full Text] [Related]
3. A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: a gene therapy approach for drug-resistant cancers.
Seth P; Katayose D; Li Z; Kim M; Wersto R; Craig C; Shanmugam N; Ohri E; Mudahar B; Rakkar AN; Kodali P; Cowan K
Cancer Gene Ther; 1997; 4(6):383-90. PubMed ID: 9408609
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
Ogretmen B; McCauley MD; Safa AR
Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
[TBL] [Abstract][Full Text] [Related]
5. Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-kappa B/p65 and c-Fos transcription factors and their interaction with the CAAT region.
Ogretmen B; Safa AR
Biochemistry; 1999 Feb; 38(7):2189-99. PubMed ID: 10026303
[TBL] [Abstract][Full Text] [Related]
6. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells.
Yu ST; Chen TM; Tseng SY; Chen YH
Biochem Biophys Res Commun; 2007 Jun; 358(1):79-84. PubMed ID: 17482571
[TBL] [Abstract][Full Text] [Related]
7. Elevated level of nuclear protein kinase C in multidrug-resistant MCF-7 human breast carcinoma cells.
Lee SA; Karaszkiewicz JW; Anderson WB
Cancer Res; 1992 Jul; 52(13):3750-9. PubMed ID: 1617646
[TBL] [Abstract][Full Text] [Related]
8. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
[TBL] [Abstract][Full Text] [Related]
9. p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells.
Matozaki T; Sakamoto C; Suzuki T; Matsuda K; Uchida T; Nakano O; Wada K; Nishisaki H; Konda Y; Nagao M
Cancer Res; 1992 Aug; 52(16):4335-41. PubMed ID: 1322785
[TBL] [Abstract][Full Text] [Related]
10. Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions.
Negrini M; Sabbioni S; Haldar S; Possati L; Castagnoli A; Corallini A; Barbanti-Brodano G; Croce CM
Cancer Res; 1994 Apr; 54(7):1818-24. PubMed ID: 8137297
[TBL] [Abstract][Full Text] [Related]
11. Immortalization of human mammary epithelial cells transfected with mutant p53 (273his).
Gollahon LS; Shay JW
Oncogene; 1996 Feb; 12(4):715-25. PubMed ID: 8632893
[TBL] [Abstract][Full Text] [Related]
12. Gain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells.
Tsou SH; Hou MH; Hsu LC; Chen TM; Chen YH
Int J Mol Med; 2016 Jan; 37(1):233-42. PubMed ID: 26572087
[TBL] [Abstract][Full Text] [Related]
13. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
14. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
[TBL] [Abstract][Full Text] [Related]
15. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene.
Casey G; Lo-Hsueh M; Lopez ME; Vogelstein B; Stanbridge EJ
Oncogene; 1991 Oct; 6(10):1791-7. PubMed ID: 1923504
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage.
Kurdistani SK; Arizti P; Reimer CL; Sugrue MM; Aaronson SA; Lee SW
Cancer Res; 1998 Oct; 58(19):4439-44. PubMed ID: 9766676
[TBL] [Abstract][Full Text] [Related]
17. Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry.
Bonsing BA; Corver WE; Gorsira MC; van Vliet M; Oud PS; Cornelisse CJ; Fleuren GJ
Cytometry; 1997 May; 28(1):11-24. PubMed ID: 9136751
[TBL] [Abstract][Full Text] [Related]
18. Influence of exogenous ras and p53 on P-glycoprotein function in immortalized rodent fibroblasts.
Kopnin BP; Stromskaya TP; Kondratov RV; Ossovskaya VS; Pugacheva EN; Rybalkina EY; Khokhlova OA; Chumakov PM
Oncol Res; 1995; 7(6):299-306. PubMed ID: 8527864
[TBL] [Abstract][Full Text] [Related]
19. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
[TBL] [Abstract][Full Text] [Related]
20. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
Park SJ; Wu CH; Safa AR
Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]